Rata Mihaela, Orton Matthew R, Tunariu Nina, Curcean Andra, Hughes Julie, Scurr Erica, Blackledge Matthew, d'Arcy James, Jiang Yun, Gulani Vikas, Koh Dow-Mu
Department of Radiology, MRI Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Eur Radiol. 2025 May;35(5):2487-2498. doi: 10.1007/s00330-024-11162-z. Epub 2024 Nov 6.
MR fingerprinting (MRF) has the potential to quantify treatment response. This study evaluated the repeatability of MRF-derived T and T relaxation times in bone metastasis, bone, and muscle in patients with metastatic prostate cancer.
This prospective single-centre study included same-day repeated MRF acquisitions from 20 patients (August 2019-October 2020). Phantom and human data were acquired on a 1.5-T MR scanner using a research MRF sequence outputting T and T maps. Regions of interest (ROIs) across three tissue types (bone metastasis, bone, muscle) were drawn on two separate acquisitions. Repeatability of T and T was assessed using Bland-Altman plots, together with repeatability (r) and intraclass correlation (ICC) coefficients. Mean T and T were reported per tissue type.
Twenty patients with metastatic prostate cancer (mean age, 70 years ± 8 (standard deviation)) were evaluated and bone metastasis (n = 44), normal-appearing bone (n = 14), and muscle (n = 20) ROIs were delineated. Relative repeatability of T measurements was 6.9% (bone metastasis), 32.6% (bone), 5.8% (muscle) and 21.8%, 32.2%, 16.1% for T measurements. The ICC of T was 0.97 (bone metastasis), 0.94 (bone), 0.96 (muscle); ICC of T was 0.94 (bone metastasis), 0.94 (bone), 0.91 (muscle). T values in bone metastasis were higher than in bone (p < 0.001). T values showed no difference between bone metastasis and bone (p = 0.5), but could separate active versus treated metastasis (p < 0.001).
MRF allows repeatable T and T measurements in bone metastasis, bone, and muscle in patients with primary prostate cancer. Such measurements may help quantify the treatment response of bone metastasis.
Question MR fingerprinting has the potential to characterise bone metastasis and its response to treatment. Findings Repeatability of MRF-based T measurements in bone metastasis and muscle was better than for T. Clinical relevance MR fingerprinting allows repeatable T and T quantitative measurements in bone metastasis, bone, and muscle in patients with primary prostate cancer, which makes it potentially applicable for disease characterisation and assessment of treatment response.
磁共振指纹成像（MRF）有量化治疗反应的潜力。本研究评估了MRF得出的T1和T2弛豫时间在转移性前列腺癌患者的骨转移灶、骨骼和肌肉中的可重复性。
这项前瞻性单中心研究纳入了20例患者（2019年8月至2020年10月）同日重复的MRF采集数据。使用输出T1和T2图谱的研究型MRF序列在1.5T MR扫描仪上采集了体模和人体数据。在两次单独的采集中绘制了三种组织类型（骨转移灶、骨骼、肌肉）的感兴趣区域（ROI）。使用Bland-Altman图评估T1和T2的可重复性，以及重复性（r）和组内相关系数（ICC）。报告了每种组织类型的平均T1和T2值。
评估了20例转移性前列腺癌患者（平均年龄70岁±8（标准差）），并勾勒出骨转移灶（n = 44）、外观正常的骨骼（n = 14）和肌肉（n = 20）的ROI。T1测量的相对可重复性在骨转移灶中为6.9%，在骨骼中为32.6%，在肌肉中为5.8%；T2测量的相对可重复性分别为21.8%、32.2%、16.1%。T1的ICC在骨转移灶中为0.97，在骨骼中为0.94，在肌肉中为0.96；T2的ICC在骨转移灶中为0.94，在骨骼中为0.94，在肌肉中为0.91。骨转移灶中的T1值高于骨骼中的T1值（p < 0.001）。骨转移灶与骨骼之间的T2值无差异（p = 0.5），但T2值可区分活跃性转移灶与经治疗的转移灶（p < 0.001）。
MRF能够在原发性前列腺癌患者的骨转移灶、骨骼和肌肉中进行可重复的T1和T2测量。此类测量可能有助于量化骨转移的治疗反应。
问题 磁共振指纹成像有表征骨转移及其对治疗反应的潜力。发现 基于MRF的T1测量在骨转移灶和肌肉中的可重复性优于T2测量。临床意义 磁共振指纹成像能够在原发性前列腺癌患者的骨转移灶、骨骼和肌肉中进行可重复的T1和T2定量测量，这使其有可能用于疾病表征和治疗反应评估。
